Dear Colleagues and Friends,
It gives me great pleasure to announce that the 16th annual scientific session of China Interventional Therapeutics (CIT) 2018 in partnership with TCT, to be held on Thursday, March 22 through Sunday, March 25, 2018 will move to Suzhou, one of the most beautiful cities in China in 2018. It will take place at the Suzhou Jinji Lake International Convention Center (JICC). CIT2018 is organized by the Chinese Medical Association, and co-sponsored by National Center for Cardiovascular Diseases of China, CIT Board of Directors, Chinese Society of Cardiology, and Cardiovascular Research Foundation, and supported by 38 international and national societies and well-known heart centers.
CIT2018 will continue to focus on C-Cooperation, I-Innovation, and T-Transition. Under the core concept and direction, CIT2018 will offer 1400+ didactic presentations, 600+ clinical cases, and 40+ live cases in its three-and-half-day program. The grand opening and plenary session will take place in the morning on Friday, March 23, 2018. Original researches are presented in the form of oral and poster abstracts, late-breaking clinical trials, topic-oriented symposia, workshops, and concurrent sessions. Basic researches, practical interventional techniques, interventional pharmacology, cardiovascular prevention, and cardiovascular imaging are also covered in-depth. CIT will make an effort to minimize gaps between evidence and practice, and to facilitate and accelerate the incorporation into clinical practice of new therapies with proven safety and efficacy in appropriately conducted clinical trials. The transition theme of CIT also highlight the current and future expansion of interventional cardiovascular practice from treatment of obstructive vascular disease to other common cardiovascular problems including structural heart disease (e.g. aortic stenosis),atrial fibrillation and hypertension.
As the largest interventional cardiology meeting in Asia-Pacific region, it is expected that more than 8,000 experts, cardiologists, radiologists, vascular medicine specialists, industrial partners and other health care professionals with a special interest in the field of interventional cardiology will attend the meeting. Participants will have the opportunities to share scientific information and the latest advances, to exchange expertise in interventional cardiology, to renew our friendship, and to increase worldwide collaboration. CIT2018 will also provide a unique opportunity for the industries to exhibit their new products and to contact with the cardiologists more closely.
Welcome to Suzhou and I look forward to your active participations in CIT2018 in partnership with TCT!
Run-lin Gao, MD, FACC, FSCAI
Professor of Medicine
Chairman, China Interventional Therapeutics (CIT)